JAK2 Exon 12 Mutation: What Detected and Not Detected Results Mean

Sample type: Whole Blood
NOT DETECTED

A not detected result means no JAK2 Exon 12 mutation was found in the tested sample. This reduces the likelihood of JAK2 Exon 12–driven disease, but does not rule out other causes of elevated blood counts or other myeloproliferative neoplasms.

What a not detected result does not exclude:

  • Other types of myeloproliferative neoplasm
  • Other genetic mutations associated with similar conditions
  • Polycythemia Vera driven by JAK2 V617F (if not yet tested)

Depending on the clinical picture, further evaluation may include:

  • JAK2 V617F mutation testing (if not already done)
  • CALR or MPL mutation analysis
  • BCR-ABL1 testing to evaluate for chronic myeloid leukaemia and other related disorders
  • Erythropoietin level to distinguish primary from secondary polycythaemia

A not detected result alongside persistent blood count abnormalities warrants continued investigation rather than reassurance that no disorder is present.

DETECTED

A detected JAK2 Exon 12 mutation means the test found a specific genetic change in the exon 12 region of the JAK2 gene. This strongly supports a diagnosis of a myeloproliferative neoplasm — most commonly Polycythemia Vera.

It means that excess red blood cell production is likely driven by an underlying acquired genetic change in the bone marrow, rather than secondary causes such as dehydration, smoking, lung disease, or high-altitude living.

What a detected result may indicate:

  • Polycythemia Vera (most likely diagnosis)
  • A clonal bone marrow disorder driven by JAK2 mutation
  • Increased risk of complications — including blood clots and, rarely, progression to myelofibrosis or acute leukaemia — if left untreated

Next steps typically include:

  • Referral to or review by a haematologist
  • Additional testing — erythropoietin levels, bone marrow biopsy, full blood count trend
  • Treatment to control blood counts and reduce complication risk, such as therapeutic phlebotomy or cytoreductive medication (hydroxyurea)

The JAK2 Exon 12 mutation test looks for specific genetic changes linked to myeloproliferative neoplasms (MPNs) — conditions where the bone marrow produces too many blood cells. It is most commonly used to help diagnose Polycythemia Vera, especially when the more common JAK2 V617F mutation has been tested and not detected. This test is typically ordered when blood counts, hemoglobin, or hematocrit are abnormally elevated without a clear secondary cause.

JAK2 Exon 12 mutations account for roughly 1–3% of Polycythemia Vera cases. JAK2 V617F is far more common, accounting for approximately 95% of cases — so Exon 12 testing is most relevant when V617F has already returned a negative result but clinical suspicion for PV remains.


How the test works

This is a PCR-based sequencing assay that examines DNA from circulating white blood cells and detects specific insertions and deletions in the exon 12 region of the JAK2 gene. It can identify mutations present in as little as approximately 5% of the sampled cells.

Important to note:

  • Only specific regions of the JAK2 gene are analysed — mutations outside exon 12 will not be detected
  • Results must always be interpreted alongside blood counts, clinical symptoms, and other laboratory findings
  • A negative Exon 12 result does not exclude other myeloproliferative neoplasms or other JAK2 mutations

Why this test is ordered

This test is typically considered when:

  • Haemoglobin, haematocrit, or red blood cell counts are persistently elevated without a clear secondary cause
  • Polycythemia Vera is suspected but JAK2 V617F testing has returned a negative result
  • Symptoms such as headaches, dizziness, itching after bathing, or unexplained fatigue are present alongside elevated blood counts
  • A haematologist is working up a possible myeloproliferative neoplasm

JAK2 V617F testing should be considered first or alongside Exon 12 testing, as V617F accounts for the majority of JAK2-positive myeloproliferative cases.

JAK2 Exon 12 Mutation
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond JAK2 Exon 12 Mutation — 10,000+ markers explained
One JAK2 Exon 12 Mutation result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

What does a detected JAK2 Exon 12 mutation mean?
It means a specific genetic mutation was found in the exon 12 region of the JAK2 gene. This strongly supports a diagnosis of Polycythemia Vera or another myeloproliferative neoplasm, and typically leads to haematology referral and further diagnostic workup.
What does a not detected JAK2 Exon 12 result mean?
No JAK2 Exon 12 mutation was found in the sample. This does not rule out other myeloproliferative neoplasms or other JAK2 mutations. If blood count abnormalities persist, further testing — including JAK2 V617F, CALR, or MPL mutation analysis — may be recommended.
What is the difference between JAK2 Exon 12 and JAK2 V617F?
Both are mutations in the JAK2 gene, but they occur in different regions. JAK2 V617F is far more common, accounting for approximately 95% of Polycythemia Vera cases. JAK2 Exon 12 mutations account for roughly 1–3% of cases and are most relevant when V617F testing is negative but clinical suspicion for PV remains.
Is JAK2 Exon 12 an inherited mutation?
No. JAK2 Exon 12 mutations are acquired (somatic) mutations — they develop in bone marrow cells during a person's lifetime and are not inherited from parents or passed to children.
What conditions are associated with JAK2 Exon 12 mutations?
Polycythemia Vera is the primary associated condition. Unlike JAK2 V617F, which is also found in essential thrombocythaemia and primary myelofibrosis, Exon 12 mutations are more specifically associated with PV — particularly the erythroid-dominant subtype characterised by isolated erythrocytosis.
What happens after a detected JAK2 Exon 12 result?
The next steps typically include hematology referral, erythropoietin level measurement, bone marrow biopsy, and a full blood count trend review. Treatment — such as phlebotomy to reduce blood viscosity or hydroxyurea to suppress overproduction — is guided by the overall clinical picture and risk assessment.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    Leukemia · 2008 View source ↗
  2. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
    The New England Journal of Medicine (NEJM) · 2007 View source ↗
  3. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
    Blood · 2007 View source ↗
  4. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
    Blood Cancer Journal · 2018 View source ↗
Article Review Log
Last reviewed April 27, 2026
Originally published April 27, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro